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Summary It has recently been found by various authors that despite a normal serum concentration of
oestradiol (E2), the percentage of non-protein-bound or free E2 is abnormally high in breast cancer patients.
Since it is the free E2 which is considered to be biologically active, confirmation of this finding would be most
relevant to the pathogenesis of breast cancer. Using Hammond's centrifugal ultrafiltration dialysis method we
have measured free E2 in heparinized plasma from 68 premenopausal women (a) at high familial risk of breast
cancer (n = 18), (b) with benign breast disease (n = 17), (c) cured of TjNoMO breast cancer at least 6 months
previously (n = 17) and (d) normal controls matched for age, parity and Quetelet index (n = 16). Sex hormone
binding globulin (SHBG) was measured as [3H]-dihydrotestosterone binding capacity. Free E2 and SHBG
were also measured in the serum of (e) postmenopausal patients having breast cancer (n =38) and (f) matched
control cancer patients (n=67). We confirmed a very good inverse correlation between log free E2 per cent
and log SHBG (P<0.0001). The regression lines for groups (a)-(d) were not statistically different. The
regression lines for groups (e) and (f) were identical and ran nearly parallel to those for groups (a)-(d) though
somewhat lower. This small difference may be ascribed to menopausal status.
Therefore, we found no difference in free E2 percentage, calculated free E2 concentration or SHBG between
premenopausal women at risk, women with benign breast disease, patients cured for early breast cancer or
having breast cancer and matched controls. However, postmenopausal breast cancer patients had a
significantly higher total serum E2 concentration and, by consequence a higher calculated free E2
concentration compared to the carefully matched control group.
Endocrine factors are thought to play a role in the
pathogenesis of cancer of the breast and various
other hormone responsive organs in man. As blood
levels of hormones are considered to be represen-
tative of their direct influence on target cells, more
sensitive and direct immunological assay methods
applied to serum or plasma have largely replaced
the determination of urinary hormone metabolites.
Oestrogens, progestins, weak androgens and
lactogenic hormones like prolactin have been the
main topic of the endocrine investigations in breast
cancer. The results of all the research performed to
date are conflicting. No unequivocal hormonal
abnormality could be discovered in patients with
breast cancer or in women at risk. It was therefore
most exciting when Siiteri et al. (1981), published
data on the elevated non-protein bound oestradiol
(free E2) fraction in the serum of breast cancer
patients. This finding appeared to be most relevant
to the alleged promotor function of E2, despite the
existence of normal serum concentrations of total
E2, since it is the free E2 fraction which is supposed
to be biologically active.
We have measured both the free E2 fraction as a
percentage of the total E2 concentration, and the
actual E2 concentration in the blood from women
at risk of breast cancer, breast cancer patients and
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matched controls. Our findings do not support the
hypothesis that the pathogenesis of breast cancer is
related to an elevated free fraction of the total E2
concentration in blood. However, the free E2
concentration, as calculated from the total E2
concentration and the free E2 fraction is shown to
be abnormally high in postmenopausal breast
cancer patients as a consequence of their elevated
total serum E2 concentration.
Subjects and methods
Subjects
Serum samples were obtained from 38 post-
menopausal breast cancer patients and a control
group of 67 women admitted for malignant
lymphoma (n=21), melanoma (n=5), cancer of the
lung (n=21) or large bowel (n=20). The two
groups were matched for age, parity and Quietelet
index (in Kgm 2) as shown in Table I. All women
were clinically judged to have normal thyroid
function.
Heparinized plasma was collected by continuous
venous sampling from 68 premenopausal women
belonging to one of the following 4 groups: 18
women at a high familial risk for breast cancer, i.e.
mother and at least one sister having breast cancer
(group R), 17 women curatively treated for early
(TINOMO) breast cancer at least 6 months ago
(group C), 17 women with histologically defined
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Table I Matching parameters for a group of
postmenopausal women having breast cancer and a
control group consisting of women having malignant
lymphoma, melanoma, cancer of the lung or large bowel
(mean values+s.d.).
Breast cancer
group Control group
(n =38) (n =67)
Age (yr) 60.2+12.0 61.6+12.6
Parity 2.3+ 1.8 2.3+2.3
Quetelet index (kgm2) 24.8 +3.5 23.9+3.8
benign proliferative breast disease (group B) and 16
normal women (group N), matched for age, parity
and Quetelet index, as shown in Table II. These
premenopausal women were known to have normal
thyroid function parameters and to use no
contraceptive pill or any other drug.
Serum and heparinized plasma were collected in
Venoject® glass tubes simultaneously from 24
healthy adult female and male individuals for
comparison of assay results in serum and plasma.
Table II Matching parameters for 68 premenopausal
women (mean values+s.d.).
Group R C B N
(n=18) (n= 17) (n= 17) (n=16)
Age (yr) 38.7+7.6 40.1 +3.7 36.4+5.0 38.1 +7.4
Parity 2.1+2.1 1.9+1.7 1.2+1.1 1.8+1.3
Quetelet
index (kgm2) 2.4+0.3 2.1 +0.3 2.2+0.2 2.3+0.2
Methods ofbloodsampling
Single serum samples were drawn on first admission
in Venoject glass tubes from the 38 patients with
breast cancer and the 67 cancer patients serving as
a matched control group.
Heparinized plasma was collected over at least
7h by a continuous venous sampling technique in
the premenopausal groups R, C, B and N. This
technique gave the opportunity to observe diurnal
variation of plasma concentrations in 20min
interval samples. For the determination of the total
E2 concentration and the percentage of free EB2 21
subsequent 20min plasma samples from each
individual women were pooled. All women were
investigated between Days 18 and 24 of their
menstrual cycle. The plasma progesterone con-
centration had to be >10nmoll-1 as evidence of
an active corpus luteum. The procedure is part of a
larger investigation of hormonal patterns and breast
cancer risk (Bruning et al., 1984).
All samples had been stored at -20°C (maxi-
mum 3 years) and had not been thawed before use.
Analytical methods
Total E2 concentration was measured by a
conventional radioimmunoassay. Serum extraction
with ether was followed by Sephadex LH-20
chromatographic separation. A highly specific
antiserum raised against E2-6-0-carboxy-methyl-
oxime-bovine serum albumin was used (Bulbrook
et al., 1978). Progesterone was measured with a
commercial radioimmunoassay-kit (Farmos, Turku,
Finland).
The percentage of free E2 was measured by
centrifugal ultrafiltration dialysis of undiluted serum
or plasma at +37°C (Hammond et al., 1980). The
interassay and intraassay coefficients of variation
were 12 and 8.6% respectively.
Sex hormone binding globulin (SHBG) was
measured as [3H]-dihydrotestosterone ([3H]-DHT)
binding capacity. In the assay method concanavalin
A-sepharose was used to separate unbound [3H]-
DHT and [3H]-DHT bound to SHBG; transcortin
binding capacity was saturated with cortisol
(modified after Nisula and Dunn, 1979). Albumin
was measured colorimetrically using bromocresyl
purple (Pinnel & Northam, 1978).
Body fat mass was determined in 18 healthy
individuals by measuring body weight and the
thickness of 4 standard skinfolds with a Harpenden
skinfold caliper (Durnin & Womersley, 1974).
Results
As can be seen from Table III we have found no
significant differences for SHBG or free E2
percentage when comparing the assay results of the
serum samples from the postmenopausal breast
cancer patients and their matched controls.
However, the mean total E2 concentration in the
postmenopausal breast cancer patient group was
significantly higher (P=0.02) after logarithmic
transformation had been applied to correct for the
skewed distribution of total E, values.
Similarly, the calculated free E2 concentration
was significantly higher in the postmenopausal
breast cancer patients than in the control cancer
patients (P=0.01). No such difference could be
demonstrated between the premenopausal groups.
The mean albumin concentration in the
postmenopausal breast cancer patients was slightly
elevated (P<0.01) compared to that in the matched
control cancer patients.
The data in Table IV indicate that no significant
differences between groups were found in the
heparinized plasma samples obtained from the
premenopausal women of groups R, B, C and N.
A very good correlation between SHBG and free
E2 percentage was observed (P<0.0001). Analysis ofFREE OESTRADIOL AND BREAST CANCER 481
Table III Serum values (mean +s.d. resp. mean of log-transformed values) in
postmenopausal women with breast cancer (n =38) and female control cancer patients
(n =67).
Breast cancer group Control group P-valuea
Total E2 (pmol 1) 155.5+314.3 73.4+ 127.3 NS
Log (total E2) 1.77 1.52 P=0.02
Free E2 (%) 1.54+0.38 1.47+0.37 NS
Log (free E2%) 0.17 0.15 NS
Calculated free E2 (pmol I 1) 2.08 +4.09 1.11 +2.08 NS
Log (calculated free E2 pmoll-1) 1.95 1.68 P=0.01
SHBG (nmol DHT 1`) 44.5+28.1 44.8i+18.9 NS
Log (SHBG nmol DHTI`) 1.58 1.61 NS
Albumin (gI -1) 41.49+5.02 39.93+4.92 P<0.01
aPaired t-test.
Table IV Plasma values (mean±s.d.) in premenopausal women.a
Group R C B N
(n= 18) (n= 17) (n=17) (n =16)
Total E2 (pmol 1 ') 366.8+ 126.5 349.9+ 162.4 287.1 +77.0 331.1 + 127.3
Free E2 (%) 1.78+0.28 1.86+0.39 1.84+0.34 1.70+0.54
Calculated free E2 (pmoll 1) 6.3+1.6 4.9+ 1.4 5.0+ 1.5 5.0+ 1.6
SHBG (nmolI-1) 35.9+11.3 33.9+12.1 31.6+10.3 37.1+20.6
Albumin (gI -') 34.5 +3.58 35.12+2.26 34.95 +2.21 33.89+ 1.79
aDue to 0.8 x dilution with heparin-saline solution values are lower than may be expected in
serum.
co-variance demonstrated that the regression lines
of log free E2 percentage vs log SHBG shown in
Figure 1 were identical for groups R, B, C and N.
Figure 2 illustrates that the regression line for the
postmenopausal breast cancer patient serum
samples was identical to that for the control serum
samples, and ran nearly parallel to the line derived
from the premenopausal plasma samples, though
somewhat lower.
This was apparently due to a somewhat lower
free E2 percentage in the cancer patient sera
(P<0.03), SHBG being similar in serum and in
heparinized plasma samples. In order to exclude the
possibility that the latter difference could result
from a difference between serum and heparinized
plasma we have determined the free E2 percentage
in heparinized plasma and serum collected
simultaneously from 24 healthy individuals. Figure
3 shows an excellent correlation between the free E2
values in plasma and in serum.
The free E2 concentration was calculated from
free E2 as a percentage of the total E2
concentration. No correlation between the free E2
concentration and SHBG could be demonstrated.
Log free E2 percentage was not correlated with
age (n= 108, range 26 to 82 years), body weight
(n= 108, range 45 to 103 kg) or body fat mass
(n= 18, range 6-30kg).
Discussion
Moore et al. (1982) gave support to Siiteri's
preliminary data showing that in premenopausal
women with stage 2 breast cancer serum E2
concentrations were normal, but free E2
concentrations (not only percentages of the total E2
concentrations) were significantly elevated. In
postmenopausal patients these investigators found
both total and free E2 to be abnormally high. Reed
et al. (1983) confirmed that the free E2 fractions of
the total E2 concentration in the plasma of
postmenopausal women with breast disease were
elevated.
We cannot support these findings as our results
do not demonstrate any elevation of the free E2
fraction in women with premenopausal or post-
menopausal breast cancer or premenopausal benign
breast disease compared to control values. Pre-
menopausal women with a relatively high risk of
breast cancer because of their family history or of
previous breast cancer showed similarly normal free
E2 fraction values. The total E2 concentration was
found to be significantly elevated in the post
menopausal breast cancer patient group compared
to the control group which was composed 'of
patients with other cancers, carefully matched for
age, parity and Quetelet's body mass index. This482 P.F. BRUNING et al.
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Figure 1 Regression analysis of the logarithmic transformation of the SHBG DHT-binding capacity to the
percentage free E2 for premenopausal women at high familial risk of breast cancer (group R), cured for early
breast cancer (group C), with benign breast disease (group B) and their normal matched controls (group N).
(a) Group R y= -0.35x+0.79; r=0.63; P<0.01; (b) Group C y= -0.40x+0.82; r=0.58; P<0.01; (c) Group B
y = -0.33x +0.76; r =0.62; P <0.01; (d) Group N y = -0.39x+0.85; r =0.79; P<0.01. Differences between the
groups are statistically not significant (analysis of co-variance).
finding is consistent with data obtained by Moore
et al. (1982).
Although Reed et al. (1983) used an equilibrium
dialysis technique, Moore et al. (1982) and Siiteri et
al. (1981) used the same centrifugal ultrafiltration
dialysis method as we did to determine the free E2
fraction (Hammond et al. (1980). There were no
differences in the [3H]-DHT binding capacity of
SHBG or albumin concentrations between our
groups which could explain the discrepancies
between our data and the free E2 results obtained
by Moore et al. and Reed et al. The difference of
albumin concentrations between our post-
menopausal patient groups would rather be in
favour of a smaller free E2 fraction in breast cancer
patients, as serum albumin represents a major
compartment of protein-bound E2.
We could confirm the strong inverse correlation
between SHBG and free E2 percentage (not free E2
concentration) as was demonstrated before (Siiteri
et al., 1981, Moore et al., 1982, Reed et al., 1983).
However, we have no indication that, as Moore et
al. (1982) concluded, for a given SHBG concen-
tration less E2 would be bound in breast cancer
patients than in the control population since the
regression lines for log free E2 percentage vs log
SHBG are identical for our breast cancer groups
and their respective matched control groups.
A small, but statistically significant difference in
free E2 percentage was observed between the
premenopausal plasma samples and the
postmenopausal serum samples. This difference
could not be ascribed to the difference between
serum and heparinized plasma itself as shown in
Figure 3.
An inverse correlation between SHBG and excess
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Figure 2 Regression analysis of the logarithmic
transformation of the SHGB DHT-binding capacity to
the percentage free E2 for 68 premenopausal women
(groups R, C, B and N; heparin plasma samples; 0)
and for 38 postmenopausal patients having breast cancer
(serum samples; 0). Data of 67 postmenopausal cancer
patient control group are not shown. Premenopausal
group: y= -0.39x+0.84; r=0.71; P<0.001; Breast
cancer group: y= -0.33x+0.70; r=0.76; P<0.001;
Cancer patient control group: y= -0.34x+0.71; r=0.75;
P<0.001. Differences between the groups are
statistically not significant (analysis ofco-variance).
body weight was reported by De Moor & Joosens
(1970) and more recently confirmed in massively
obese women (Kopelman et al., 1980) and in
postmenopausal women with endometrial cancer
(Nisker et al., 1980). However, we could not find
significant correlations between free E2 percentage
and age, body weight or body fat mass respectively.
We conclude that some other factor(s), possibly
related to the menopausal status, may be involved.
If free E2 in blood is to be regarded as important
since it represents the biologically active fraction of
the total E2 concentration, then the free E2 con-
centratioh, not the mere free E2 fraction expressed
as a percentage of the total E2 concentration should
be considered. Our data do not support a role for a
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Figure 3 Regression of percentage free E2 in serum
to that in heparinized plasma for 24 healthy subjects;
y=x-0.02; r=0.97; P<O.OOO1. (@)=female; (0)
=male.
measurable elevated blood free E2 fraction.
However, we did find an elevated total E2 concen-
tration in the serum of postmenopausal breast
cancer patients from which a significantly elevated
free E2 concentration could be calculated. This
increase in 'E2 -availability' may be meaningful in
the modulation of breast cancer. The discrepancy
between our findings and those of Moore et al.
(1982), using the same method to measure the free
E2 fraction, might be explained by differences in the
serum concentrations of free fatty acids which are
inversely related to the free E2 fraction (Bruning &
Bonfrer, unpublished observations).
Geographical differences in sex steroid binding to
serum proteins may exist as a result of life style or
genetic factors.
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